Immunoadsorption for haemolytic uraemic syndrome

The Lancet

Volumn 378, Issue 9797, 2011, Pages 1120-1122

  Kim, Jon Jin ^a  

^a EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; ECULIZUMAB; IMMUNOGLOBULIN G;

ADULT; BACTERIAL VIRULENCE; CHILD; COMPLEMENT SYSTEM; DIARRHEA; ENTEROHEMORRHAGIC ESCHERICHIA COLI; FEMALE; GERMANY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; HYPONATREMIA; IMMUNE RESPONSE; IMMUNOADSORPTION; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; TREATMENT RESPONSE;

EID: 80053291417     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61342-1     Document Type: Note

References (10)

1. Robert Koch Institute. EHEC/HUS O104:H4-the outbreak is considered to be over. July 26, 2011. http://www.rki.de/cln-110/nn-217400/EN/Home/PM-EHEC.html (accessed Aug 7, 2011).
2. Frank C, Werber D, Cramer JP, et al, for the HUS investigation team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany-preliminary report. N Engl J Med 2011; published online June 22. DOI:10.1056/NEJMoa1106483.
3. Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010; 5: 1218-28.
4. Greinacher A, Friesecke S, Abel P, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011; published online Sept 5. DOI:10.1016/S0140- 6736(11)61253-1.
5. Rasko DA, Webster DR, Sahl JW, et al. Origins of the E coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011; 365: 709-17.
6. Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol 2010; 25: 2231-40.
7. Fernández-Brando RJ, Bentancor LV, Mejias MP, et al. Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. PLoS One 2011; 6: e19136.
8. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-63.
9. Morigi M, Galbusera M, Gastoldi S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187: 172-80.
10. Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182: 6394-400